FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1522563507> ?p ?o ?g. }

• W1522563507 abstract "Abstract Background Complicated intra-abdominal infections (cIAI) remain challenging to treat because of their polymicrobial etiology including multi-drug resistant bacteria. The efficacy and safety of tigecycline, an expanded broad-spectrum glycylcycline antibiotic, was compared with imipenem/cilastatin (IMI/CIS) in patients with cIAI. Methods A prospective, double-blind, multinational trial was conducted in which patients with cIAI randomly received intravenous (IV) tigecycline (100 mg initial dose, then 50 mg every 12 hours [q12h]) or IV IMI/CIS (500/500 mg q6h or adjusted for renal dysfunction) for 5 to14 days. Clinical response at the test-of-cure (TOC) visit (14–35 days after therapy) for microbiologically evaluable (ME) and microbiological modified intent-to-treat (m-mITT) populations were the co-primary efficacy endpoint populations. Results A total of 825 patients received ≥ 1 dose of study drug. The primary diagnoses for the ME group were complicated appendicitis (59%), and intestinal (8.8%) and gastric/duodenal perforations (4.6%). For the ME group, clinical cure rates at TOC were 80.6% (199/247) for tigecycline versus 82.4% (210/255) for IMI/CIS (95% CI -8.4, 5.1 for non-inferiority tigecycline versus IMI/CIS). Corresponding clinical cure rates within the m-mITT population were 73.5% (227/309) for tigecycline versus 78.2% (244/312) for IMI/CIS (95% CI -11.0, 2.5). Nausea (31.0% tigecycline, 24.8% IMI/CIS [ P = 0.052]), vomiting (25.7% tigecycline, 19.4% IMI/CIS [ P = 0.037]), and diarrhea (21.3% tigecycline, 18.9% IMI/CIS [ P = 0.435]) were the most frequently reported adverse events. Conclusion This study demonstrates that tigecycline is as efficacious as imipenem/cilastatin in the treatment of patients with cIAI." @default.
• W1522563507 created "2016-06-24" @default.
• W1522563507 creator A5009915446 @default.
• W1522563507 creator A5012501258 @default.
• W1522563507 creator A5013759582 @default.
• W1522563507 creator A5017713779 @default.
• W1522563507 creator A5044798474 @default.
• W1522563507 creator A5055169513 @default.
• W1522563507 creator A5068770979 @default.
• W1522563507 creator A5077800043 @default.
• W1522563507 creator A5078296269 @default.
• W1522563507 date "2005-10-19" @default.
• W1522563507 modified "2023-10-07" @default.
• W1522563507 title "A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]" @default.
• W1522563507 cites W1964311223 @default.
• W1522563507 cites W1988750503 @default.
• W1522563507 cites W2000521726 @default.
• W1522563507 cites W2007340701 @default.
• W1522563507 cites W2031303083 @default.
• W1522563507 cites W2034482054 @default.
• W1522563507 cites W2069416660 @default.
• W1522563507 cites W2076728316 @default.
• W1522563507 cites W2081535598 @default.
• W1522563507 cites W2083349894 @default.
• W1522563507 cites W2089068120 @default.
• W1522563507 cites W2109434703 @default.
• W1522563507 cites W2113588525 @default.
• W1522563507 cites W2116352191 @default.
• W1522563507 cites W2149365938 @default.
• W1522563507 cites W2153590024 @default.
• W1522563507 cites W2156737450 @default.
• W1522563507 cites W2170206890 @default.
• W1522563507 cites W2402130958 @default.
• W1522563507 cites W4235696763 @default.
• W1522563507 cites W4252160214 @default.
• W1522563507 doi "https://doi.org/10.1186/1471-2334-5-88" @default.
• W1522563507 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1277826" @default.
• W1522563507 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16236177" @default.
• W1522563507 hasPublicationYear "2005" @default.
• W1522563507 type Work @default.
• W1522563507 sameAs 1522563507 @default.
• W1522563507 citedByCount "144" @default.
• W1522563507 countsByYear W15225635072012 @default.
• W1522563507 countsByYear W15225635072013 @default.
• W1522563507 countsByYear W15225635072014 @default.
• W1522563507 countsByYear W15225635072015 @default.
• W1522563507 countsByYear W15225635072016 @default.
• W1522563507 countsByYear W15225635072017 @default.
• W1522563507 countsByYear W15225635072018 @default.
• W1522563507 countsByYear W15225635072019 @default.
• W1522563507 countsByYear W15225635072020 @default.
• W1522563507 countsByYear W15225635072021 @default.
• W1522563507 countsByYear W15225635072022 @default.
• W1522563507 countsByYear W15225635072023 @default.
• W1522563507 crossrefType "journal-article" @default.
• W1522563507 hasAuthorship W1522563507A5009915446 @default.
• W1522563507 hasAuthorship W1522563507A5012501258 @default.
• W1522563507 hasAuthorship W1522563507A5013759582 @default.
• W1522563507 hasAuthorship W1522563507A5017713779 @default.
• W1522563507 hasAuthorship W1522563507A5044798474 @default.
• W1522563507 hasAuthorship W1522563507A5055169513 @default.
• W1522563507 hasAuthorship W1522563507A5068770979 @default.
• W1522563507 hasAuthorship W1522563507A5077800043 @default.
• W1522563507 hasAuthorship W1522563507A5078296269 @default.
• W1522563507 hasBestOaLocation W15225635071 @default.
• W1522563507 hasConcept C126322002 @default.
• W1522563507 hasConcept C141071460 @default.
• W1522563507 hasConcept C203092338 @default.
• W1522563507 hasConcept C2777027569 @default.
• W1522563507 hasConcept C2777437143 @default.
• W1522563507 hasConcept C2779631663 @default.
• W1522563507 hasConcept C2779802037 @default.
• W1522563507 hasConcept C2781255259 @default.
• W1522563507 hasConcept C2908647359 @default.
• W1522563507 hasConcept C501593827 @default.
• W1522563507 hasConcept C535046627 @default.
• W1522563507 hasConcept C71924100 @default.
• W1522563507 hasConcept C86803240 @default.
• W1522563507 hasConcept C89423630 @default.
• W1522563507 hasConcept C90924648 @default.
• W1522563507 hasConcept C94665300 @default.
• W1522563507 hasConcept C99454951 @default.
• W1522563507 hasConceptScore W1522563507C126322002 @default.
• W1522563507 hasConceptScore W1522563507C141071460 @default.
• W1522563507 hasConceptScore W1522563507C203092338 @default.
• W1522563507 hasConceptScore W1522563507C2777027569 @default.
• W1522563507 hasConceptScore W1522563507C2777437143 @default.
• W1522563507 hasConceptScore W1522563507C2779631663 @default.
• W1522563507 hasConceptScore W1522563507C2779802037 @default.
• W1522563507 hasConceptScore W1522563507C2781255259 @default.
• W1522563507 hasConceptScore W1522563507C2908647359 @default.
• W1522563507 hasConceptScore W1522563507C501593827 @default.
• W1522563507 hasConceptScore W1522563507C535046627 @default.
• W1522563507 hasConceptScore W1522563507C71924100 @default.
• W1522563507 hasConceptScore W1522563507C86803240 @default.
• W1522563507 hasConceptScore W1522563507C89423630 @default.
• W1522563507 hasConceptScore W1522563507C90924648 @default.
• W1522563507 hasConceptScore W1522563507C94665300 @default.
• W1522563507 hasConceptScore W1522563507C99454951 @default.
• W1522563507 hasIssue "1" @default.

• next